References
- Nanduri J, Kazura JW. Clinical and laboratory aspects of filariasis. Clin Microbiol Rev. 1989;2:39–50.
- Palumbo E. Filariasis: diagnosis, treatment and prevention. Acta Biomed. 2008;79:106–9.
- Fernando SD, Rodrigo C, Rajapakse S. Current evidence on the use of antifilarial agents in the management of bancroftian filariasis. J Trop Med. 2011;2011:175941.
- Grove DI. Tissue nematodes including trichinosis, dracunculiasis, and the filariosis. In: Bennett JE, Dolin R, Mandell GL, editors. Douglas, and Bennett’s Principles and practices of infectious diseases. 6th edn. Philadelphia, PA: Churchill Livingstone; 2005. pp. 3267–3276.
- World Health Organization. Weekly Epidemiol Rep. 2012;37:345–56.
- Center for Deseases Control. Recommendation of the International Task Force for Disease Eradication. Morbidity and Mortality Weekly Report 42. 1993. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00025967.htm
- Ichimori K, Crump A. Pacific collaboration to eliminate lymphatic filariasis. Trends Parasitol. 2007;23:36–40.
- World Health Organization. Preparing and implementing a national plan to eliminate lymphatic filariasis. Geneva: WHO; 2000.
- Addiss D. The global alliance to eliminate lymphatic filariasis. The 6th Meeting of the global alliance to eliminate lymphatic filariasis: a half-time review of lymphatic filariasis elimination and its integration with the control of other neglected tropical diseases. Parasit Vectors. 2010;3:100.
- World Health Organization. Proc. 6th Meeting of the GAELF on Half-time in LF elimination: teaming up with NTDs. Seoul, Korea, 2010.
- Rosenblatt JE. Laboratory diagnosis of infections due to blood and tissue parasites. Clin Infect Dis. 2009;49:1103–8.
- Weil GJ, Ramzy RM, Chandrashekar R, Gad AM, Lowrie RC, Faris R. Parasite antigenemia without microfilaremia in bancroftian filariasis. Am J Trop Med Hyg. 1996;55:333–7.
- Chanteau S, Glaziou P, Luquiaud P, Plichart C, Moulia-Pelat JP, Cartel JL. Og4C3 circulating antigen, anti-Brugia malayi IgG and IgG4 titers in Wuchereria bancrofti infected patients, according to their parasitological status. Trop Med Parasitol. 1994;45:255–7.
- Rocha A, Addiss D, Ribeiro ME, Norões J, Baliza M, Medeiros Z, et al.. Evaluation of the Og4C3 ELISA in Wuchereria bancrofti infection: infected persons with undetectable or ultra-low microfilarial densities. Trop Med Int Health. 1996;1:859–64.
- Rao RU, Atkinson LJ, Ramzy RM, Helmy H, Farid HA, Bockarie MJ, et al.. A real-time PCR-based assay for detection of Wuchereria bancrofti DNA in blood and mosquitoes. Am J Trop Med Hyg. 2006;74:826–32.
- Weil GJ, Liftis F. Identification and partial characterization of a parasite antigen in sera from humans infected with Wuchereria bancrofti. J Immunol. 1987;138:3035–41.
- Malla N, Elango A, Pani SP, Mahajan RC. Kinetics of microfilaraemia & antigenaemia status by Og(4)C(3) ELISA in bancroftian filariasis. Indian J Med Res. 2007;126:567–74.
- Weil GJ, Lammie PJ, Weiss N. The ICT filariasis test: a rapid-format antigen test for diagnosis of bancroftian filariasis. Parasitol Today. 1997;10:401–4.
- Nuchprayoon S, Porksakorn C, Junpee A, Sanprasert V, Poovorawan Y. Comparative assessment of an Og4C3 ELISA and an ICT filariasis test: a study of Myanmar migrants in Thailand. Pac J Allergy Immunol. 2003;21:253–7.
- Nguyen NL, Plichart C, Esterre P. Assessment of immunochromatographic test for rapid lymphatic filariasis diagnosis. Parasite. 1999;16:355–8.
- Gass K, Beau de Rochars MV, Boakye D, Bradley M, Fischer PU, Gyapong J, et al.. A multicenter evaluation of diagnostic tools to define endpoints for programs to eliminate Bancroftian filariosis. PLoS Negl Trop Dis. 2012;6(1):e1479.
- World Health Organization. The PacELF Way: towards the elimination of lymphatic filariasis from the Pacific, 1999–2005. Geneva: WHO; 2010.
- Dreyer G, Lins R, Norões J, Rizzo JA, Figueredo-Silva J. Sensitivity of the immunochromatographic card test relative to detection of adult Wuchereria bancrofti worms by ultrasound. Am J Trop Med Hyg. 2008;78:28–34.
- Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol. 2010;126:39–44.
- Nutman TB. Evaluation and differential diagnosis of marked, persistent eosinophilia. Immunol Allergy Clin North Am. 2007;27:529–49.
- Tefferi A. Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment. Mayo Clin Proc. 2005;80:75–83.
- Mou Y, Plichart C, Legrand AM, Mallet HP, Cerf N, Nguyen NL. Assessment of the prevalence of lymphatic filariasis in French Polynesia in 2008. French Polynesia: a special epidemiological situation. Bull Epidémiol Hebdomadaire. 2009;48-49-50:497–528.
- Simonsen PE, Magesa SM. Observations on false positive reactions in the rapid NOW Filariasis card test. Trop Med Int Health. 2004;9:1200–2.
- Burkot TR, Durrheim DN, Melrose WD, Speare R, Ichimori K. The argument for integrating vector control with multiple drug administration campaigns to ensure elimination of lymphatic filariasis. Filaria J. 2006;5:10.
- Pichon G. Limitation and facilitation in the vectors and other aspects of the dynamics of filarial transmission: the need for vector control against Anopheles-transmitted filariasis. Ann Trop Med Parasitol. 2002;96:43–52.